The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Updates on the diagnosis, risk stratification and management of HL
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses recent updates in the diagnosis and management of Hodgkin lymphoma (HL), and the need to improve methods of diagnosing uncommon subsets, such as nodular lymphocyte-predominant HL. Prof. Ansell also comments on the growing role of novel technologies and biomarkers in the risk stratification of patients with HL. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.
